China-based Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262) announced plans to subscribe to Hong Kong-headquartered NeuroThree Therapeutics, Inc.’s Pre-Series A financing round, investing USD 3.5 million for 12.5 million shares. Upon completion of the transaction, Nhwa will hold a 10.448% stake in NeuroThree.
Company Background
Founded in 2021, NeuroThree focuses on developing breakthrough therapies for central nervous system (CNS) diseases, with a particular emphasis on neuroexcitability and neurodegenerative diseases. Its robust product pipeline includes a clinical-stage small molecule for epilepsy, a small molecule drug for Parkinson’s disease and pain, and an siRNA drug in the pre-clinical stage.-Fineline Info & Tech
Leave a Reply